00:00Dr. Ramondo, in the context of prevention to make investments feasible in the short term,
00:05What role can biosimilar drugs play in contributing to a healthcare system that focuses on the prevention and management of chronic conditions?
00:12Well, prevention is certainly a health enabler, there are two essential prerequisites,
00:19the first concerns the training and education of citizens, the second the creation of the necessary paths for the provision of
00:27prevention.
00:28In both cases, resources are needed that the healthcare system must identify and reallocate.
00:35In this path, Sandots presents itself as an organization capable of supporting political decision makers and obviously technical operators
00:44through a very important portfolio that contains biosimilar drugs.
00:49Biosimilar drugs are biological macromolecules that become available when patent protection expires.
00:57of assets approved for the treatment of oncological, immunological and neurodegenerative diseases.
01:04Sandots currently markets 13 biosimilar products, the contribution it has already expressed is important because, as reported in the document
01:13by AIFA
01:13In 2025, biosimilar drugs could save up to half a billion euros.
01:20Last week, Sandots officially communicated its strategy to the global market.
01:26We will launch 100 new biosimilar drugs, seizing an opportunity emerging in the market related to upcoming patent expirations.
01:3470 will be launched by 2035 and 100 by 2040.
01:40It is an important path that will certainly allow the generation of savings that can be reallocated for the introduction of
01:47innovation and for the provision of prevention.
01:49Thank you.
Commenti